Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1)
The summary for the Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1): -Purpose. The goal of this funding opportunity announcement (FOA) is to accelerate the development of safe and effective medical products to mitigate and treat thrombocytopenia and to enhance platelet regeneration after radiation exposure from radiological and nuclear terrorist attacks. Specifically, this new initiative will support research and development of promising new approaches and medical products to enhance platelet regeneration and yield improved survival. -Among the most important medical countermeasures against acute radiation syndrome are those that will treat or mitigate its hematopoietic component. Certain radiation exposures can cause severe damage to the bone marrow, which can have dramatic effects on circulating blood cells, including platelets, neutrophils, lymphocytes, and erythrocytes,. Platelets play an essential role in hemostasis and thrombosis. As the level of circulating platelets drops below 20,000/mm3 (a condition referred to as severe thrombocytopenia ), the risk to an affected individual for catastrophic hemorrhage increases markedly. Severe thrombocytopenia is clearly a contributor to mortality following radiation exposure. Currently, there is no approved therapeutic drug in the Strategic National Stockpile for this radiation-induced complication. -Mechanism of Support. This FOA will utilize the NIH Challenge Grant (RC1) award mechanism.
|Federal Grant Title:||Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1)|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-AI-07-036|
|Type of Funding:||Grant|
|CFDA Descriptions:||Allergy, Immunology and Transplantation Research|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Jan 10, 2008|
|Posted Date:||Sep 27, 2007|
|Creation Date:||Nov 09, 2007|
|Archive Date:||Feb 09, 2008|
|Total Program Funding:||$4,000,000|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses State governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Similar Government Grants
- • Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
- • Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
- • Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
- • NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
- • Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 C...
- • Center for HIV/AIDS Vaccine Immunology (CHAVI)
- • Genomics of Transplantation Cooperative Research Program
- • Asthma and Allergic Diseases Cooperative Research Centers
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...